22nd Century集团已正式向美国食品药品监督管理局提交VLN®减害烟草产品的MRTP（改良风险烟草产品）续期申请。该产品是目前全球唯一获得FDA授权、专门设计用于帮助吸烟者降低吸烟量的可燃性烟草制品。
VLN®系列产品通过显著降低尼古丁含量（较传统香烟减少95%），在维持吸烟仪式感的同时，从根源上减弱烟草依赖。此次续期申请若获批，将延续该产品在帮助成年吸烟者逐步戒断尼古丁依赖方面的独特市场地位。
值得注意的是，FDA此前授予VLN®的授权书中明确强调，该产品"并非完全无害"，但科学证据表明其相较于传统卷烟能有效降低尼古丁摄入量。这一特性使其成为吸烟者迈向无烟生活的过渡性选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.